You just read:

Mirati Presents Data From Ongoing Phase 2 Clinical Trial Of Mocetinostat In Combination With Durvalumab At The SITC 33rd Annual Meeting

News provided by

Mirati Therapeutics, Inc.

Nov 09, 2018, 08:30 ET